Satyabrata Dandapat

Satyabrata Dandapat


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
SBSuresh Bindu
Suresh Bindu
SDSatyabrata Dandapat
Satyabrata Dandapat
RMRajendran Manikandan
Rajendran Manikandan
MDMurali Dinesh
Murali Dinesh
ASAnbazhagan Subbaiyan
Anbazhagan Subbaiyan
Kuldeep DhamaKuldeep Dhama
Kuldeep Dhama
Trained immunity is a renewed concept of innate immune memory that facilitates the innate immune system to have the capacity to remember and train cells via metabolic and transcriptional events to enable them to provide nonspecific defense against the subsequent encounters with a range of pathogens and acquire a quicker and more robust immune response, but different from the adaptive immune memory. Reversing the epigenetic changes or targeting the immunological pathways may be considered potential therapeutic approaches to counteract the hyper-responsive or hypo-responsive state of trained immunity. The efficient regulation of immune homeostasis and promotion or inhibition of immune responses is required for a balanced response. Trained immunity-based vaccines can serve as potent immune stimuli and help in the clearance of pathogens in the body through multiple or heterologous effects and confer protection against nonspecific and specific pathogens. This review highlights various features of trained immunity and its applications in developing novel therapeutics and vaccines, along with certain detrimental effects, challenges as well as future perspectives.

1 December 2016 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
VCVishal Chander
Vishal Chander
SCSoumendu Chakravarti
Soumendu Chakravarti
VGVikas Gupta
Vikas Gupta
SNSukdeb Nandi
Sukdeb Nandi
MSMithilesh Singh
Mithilesh Singh
VGV.K. Gupta
V.K. Gupta

30 March 2023 in Poultry Science
Verified
Journal Article
Open access
BKB.S. Ananda Kumar
B.S. Ananda Kumar
SPSivasankar Panickan
Sivasankar Panickan
SBSuresh Bindu
Suresh Bindu
VKVimal Kumar
Vimal Kumar
SRSaravanan Ramakrishnan
Saravanan Ramakrishnan
SDSatyabrata Dandapat
Satyabrata Dandapat
An immunization experiment was conducted in specific pathogen-free chickens with the inactivated Newcastle disease virus (NDV) vaccine encapsulated in the poly-(lactic-co-glycolic) acid (PLGA) nanoparticles (NP) to evaluate its immunogenicity and protective efficacy. The NDV vaccine was prepared by inactivating one virulent Indian strain of NDV belonging to Genotype VII by using beta-propiolactone. PLGA nanoparticles encapsulating inactivated NDV were prepared by the solvent evaporation method. Scanning electron microscopy and zeta sizer analysis revealed that the (PLGA+NDV) NP were spherical, with an average size of 300 nm, having a zeta potential of -6 mV. The encapsulation efficiency and loading efficiency were 72% and 2.4%, respectively. On immunization trial in chicken, the (PLGA+NDV) NP induced significantly (P < 0.0001) higher levels of HI and IgY antibodies with the peak HI titer of 28 and higher expression of IL-4 mRNA. The consistency of higher antibody levels suggests slow and pulsatile release of the antigens from the (PLGA+NDV) NP. The nano-NDV vaccine also induced cell mediated immunity with higher expression of IFN-γ indicating strong Th1 mediated immune responses in contrast to the commercial oil adjuvanted inactivated NDV vaccine. Further, the (PLGA+NDV) NP afforded 100% protection against the virulent NDV challenge. Our results suggested that PLGA NP have adjuvant potential on induction of humoral as well as Th1 biased cell mediated immune responses and also enhanced protective efficacy of the inactivated NDV vaccine. This study provides an insight for development of PLGA NP based inactivated NDV vaccine using the same genotype circulating in the field as well as for other avian diseases at exigencies.

10 May 2024 in Veterinary Quarterly
Verified
Journal Article
Open access
SDSatyabrata Dandapat
Satyabrata Dandapat
SBSuresh Bindu
Suresh Bindu
GSGaurav Kumar Sharma
Gaurav Kumar Sharma
SPSivasankar Panickan
Sivasankar Panickan
SNSukdeb Nandi
Sukdeb Nandi
KDKuldeep Dhama
Kuldeep Dhama
Duck plague (DP) is an acute, contagious and fatal disease, caused by duck enteritis virus (DEV), with worldwide distribution causing several outbreaks and posing severe economic losses. The present study was carried out with a goal of development of a live attenuated cell culture based DP vaccine using an Indian strain of DEV and evaluation of its safety, efficacy along with complete genome analysis. The live attenuated DP vaccine (DPvac/IVRI-19) was developed by serial propagation of a virulent isolate of DEV (DEV/India/IVRI-2016) in the chicken embryo fibroblast (CEF) primary cell culture. Adaptation of DEV in CEF cell culture was indicated by more rapid appearance of cytopathic effects (CPE) and gradual increase of virus titre, which reached up to 107.5 TCID50/mL after 41 passages. The safety, immunogenicity and efficacy of the vaccine were determined by immunization trials in ducklings. The DPvac/IVRI-19 was found to be avirulent and completely safe in the ducklings. Further, the vaccine induced both humoral and cell mediated immune responses and afforded 100% protection against the virulent DEV challenge. A comparison of the whole genome of DPvac/IVRI-19 (MZ911871) and DEV/India/IVRI-2016 (MZ824102) revealed significant number of mutations, which might be associated with viral attenuation. Phylogenetic tree of DEV/India/IVRI-2016 revealed its evolutionary relationship with other DEV isolates, but it formed a separate cluster with certain unique mutations. Thus, with the proven safety and 100% efficacy, the DPvac/IVRI-19 is suitable for large scale production with precisely pure form of vaccine and has potential utility at national and global levels.

23 March 2022 in Microbial Pathogenesis
Verified
Journal Article
Closed access
JKJyoti Kumar
Jyoti Kumar
SDSatyabrata Dandapat
Satyabrata Dandapat
SPSivasankar Panickan
Sivasankar Panickan
AKAjay Kumar
Ajay Kumar
MSMithilesh Singh
Mithilesh Singh
Kuldeep DhamaKuldeep Dhama
Kuldeep Dhama

21 July 2022 in Microbiology Resource Announcements
Verified
Journal Article
Open access
SDSatyabrata Dandapat
Satyabrata Dandapat
SBSuresh Bindu
Suresh Bindu
GSGaurav Kumar Sharma
Gaurav Kumar Sharma
GSG. Saikumar
G. Saikumar
Molecular characterization of Indian isolates of duck enteritis virus (DEV) so far has been limited to a few selected genomic regions. Here, we report the complete genome sequence of an isolate, DEV/India/IVRI-2016, from southern India that is 158,091 bp in length.